STREPTOCOCCAL DISEASE IN NEONATES

新生儿链球菌病

• 批准号: 2315429
• 负责人: LEONARD WEISMAN
• 金额: $ 16.62万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-30 至 1998-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2315429
• 关键词: STREPTOCOCCAL; DISEASE; NEONATES

The National Institute of Child Health and Human Development plans to conduct a study that will recruit three groups of infants: infants who have developed early onset (less than or equal to 7 days of age) invasive GBS (Types Ia, Ib, II, and III) disease ("cases"), and two groups of infants who have not developed early onset GBS despite having been colonized shortly after birth: one group with colonization at multiple (>2) sites ("control group I") and one with colonization at fewer surface sites ("control group II"). GBS disease will be defined as an infection associated with isolation of GBS from a normally sterile site, such as cerebrospinal fluid or blood. A total of 240 cases, ca. 480 controls for control group I, and ca. 1440 controls for control group II will be recruited from participating hospitals over a period of 30 months. With the annual incidence rates varying from about 2-5/1000 live births, in different geographic areas and populations, Baylor College of Medicine is one of the participating collaborative center that is helping to meet the target goal of 240 cases within the assembly period of 30 months.

国家儿童健康与人类发展研究所 进行一项将招募三组婴儿的研究：婴儿 已经发展早期发作（小于或等于7天的年龄）侵入性 GBS（IA类型，IB，II和III）疾病（“病例”），两组 尽管曾经有过早期发病的婴儿 出生后不久殖民：一组在多个处定植 （> 2）站点（“对照组I”），一个地面定植的位置 站点（“对照组II”）。 GBS病将被定义为感染 与正常无菌位点隔离GB的GB有关，例如 脑脊液或血液。 总共240例，约。 480个控件 对照组I和CA。对照组II的1440控制将是 在30个月的时间内从参与医院招募。和 年度发病率从约2-5/1000个活产率不等 不同地理区域和人口，贝勒医学院是 参与的合作中心之一，正在帮助满足 在30个月的组装期内的目标目标为240个案例。